Muckle Wells Syndrome News and Research

RSS

Small molecule inhibitor of the NLRP3 inflammasome for treating autoinflammatory diseases

Researchers described the preclinical profile of JT002, a novel and orally bioavailable small molecule inhibitor of the NLRP3 inflammasome.

24 Aug 2023

Groundbreaking study broadens spectrum of cryopyrin-associated periodic syndromes

A research team from the University of Helsinki, Helsinki University Hospital and Folkhälsan Institute of Genetics in Helsinki, Finland, have identified a new genetic mutation that alters the function of cryopyrin and leads to a life-long periodic inflammation of the cornea, the transparent window of the human eye. Patients who carry the mutation also develop corneal opacities that compromise vision.

29 Jan 2018

Scientists identify epigenetic alterations involved in autoinflammatory diseases

Researchers from the Chromatin and Disease group of the Bellvitge Biomedical Research Institute, led by Dr. Esteban Ballestar, have identified for the first time epigenetic alterations in autoinflammatory diseases, particularly in cryopyrin-associated periodic syndromes (CAPS).

8 Jul 2016

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Scientists at Trinity College Dublin have uncovered a marvel molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new non-invasive treatments for arthritis, multiple sclerosis and Muckle-Wells syndrome, among a myriad of other inflammatory diseases.

18 Feb 2015

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010